FDA nod to Merck’s cholesterol pill opens a new frontier in cardiovascular care
The FDA approved Merck’s Lipfendra, the first non-injectable pill targeting PCSK9 to significantly reduce LDL cholesterol in patients not adequately controlled by statins. Clinical trials showed over 55% LDL reduction, and the drug was reviewed under the FDA's fast-track program.
Mentioned
Related Signal
Adjacent reporting
- FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
- FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
- Merck won FDA approval for the first cholesterol pill to rival powerful injectables
- Drugmaker Merck announces approval of new cholesterol-fighting drug
- FDA approves new pill to slash cholesterol levels